OSLO, Norway, Oct. 9, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that the Company and its collaborators at
Orano Med will present data and analyses from preclinical studies
with 212Pb-NNV003, a CD37 targeting
alpha-radioimmunotherapy for the treatment of leukaemia and
lymphoma at the 2019 Annual Congress of the European Association of
Nuclear Medicine (12-16 October, Barcelona, Spain).
In the study, the efficacy of 212Pb-NNV003 was
compared with ibrutinib in a disseminated mouse model using the
ibrutinib-resistant cell line MEC-2. Ibrutinib is a Bruton's
tyrosine kinase (BTK) inhibitor that forms part of the standard of
care for chronic lymphocytic leukaemia (CLL) and non-Hodkgin's
lymphoma (NHL), alongside chemotherapy and anti-CD20 antibody
therapy.
The study showed that a single injection of
212Pb-NNV003 is safe and effective for the treatment of
CD37-positive CLL and NHL in preclinical models, with promising
efficacy in an ibrutinib-resistant CLL model.
Presentation details are as follows:
Targeted alpha therapy with 212Pb-NNV003 is
efficient in treatment of ibrutinib-resistant chronic lymphocytic
leukaemia in preclinical model
Authors: A. Saidi, H. Heyerdahl, A.F. Maaland, J. Torgue, and J.
Dahle
Session: 405 - M2M - Parallel Session: Antibody-Based
Radionuclide Therapy
Abstract: OP-134
Date / time: Sunday 13 October, 14:30-14:41 CEST
The abstract book can be downloaded at
https://eanm19.eanm.org/abstract-book/
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking statements.
These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances, since they
relate to events and depend on circumstances that will occur in the
future and which, by their nature, will have an impact on Nordic
Nanovector's business, financial condition and results of
operations. The terms "anticipates", "assumes", "believes", "can",
"could", "estimates", "expects", "forecasts", "intends", "may",
"might", "plans", "should", "projects", "targets", "will", "would"
or, in each case, their negative, or other variations or comparable
terminology are used to identify forward-looking statements. These
forward-looking statements are not historic facts. There are a
number of factors that could cause actual results and developments
to differ materially from those expressed or implied in the
forward-looking statements. Factors that could cause these
differences include, but are not limited to, risks associated with
implementation of Nordic Nanovector's strategy, risks and
uncertainties associated with the development and/or approval of
Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise
Betalutin®, technology changes and new products in Nordic
Nanovector's potential market and industry, Nordic Nanovector's
freedom to operate (competitors patents) in respect of the products
it develops, the ability to develop new products and enhance
existing products, the impact of competition, changes in general
economy and industry conditions, and legislative, regulatory and
political factors. No assurance can be given that such expectations
will prove to have been correct. Nordic Nanovector disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
This information is subject to a duty of disclosure pursuant to
Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-presentations-at-the-annual-congress-of-the-european-association-of-nuclear-medici,c2928511